Table 1 Baseline disease data
From: Tolerance and efficacy of off-label anti-interleukin-1 treatments in France: a nationwide survey
Disease | No. of patients | M/F | Median age * (y) (IQR, TR) | Median disease duration * (y) (IQR) |
|---|---|---|---|---|
AOSD | 35 | 12/23 | 40.9 (22.4, 21.4-79.4) | 4.4 (7.4, 0.04-46.9) |
Gout | 28 | 24/4 | 57.4 (11.5, 29.0-86.3) | 1.6 (8.5, 0.03-37.2) |
SJIA | 27 | 17/10 | 7.3 (9.35, 2.1-29.1) | 1.4 (5.2, 0.11-24.1) |
CAPS | 21 | 11/10 | 25.9 (22.5, 3.8-66.3) | 20.7 (25.3, 0.5-54.7) |
FMF | 14 | 4/11 | 21.1 (33.7, 5.9-60.8) | 13.1 (19.5, 5.3-42.9) |
MKD | 12 | 5/7 | 9.5 (14.9, 1.4-36.1) | 9.5 (15.6, 0.83-34.9). |
SAPHO | 9 | 4/5 | 49.1 (18.8, 25.2-59.0) | 10.6 (14, 1.2-26.3) |
Schnitzler’s syndrome | 7 | 5/2 | 55.3 (22.0, 49.9-76.2) | 7.4 (6.2, 3.5-13.7) |
Spondyloarthritis | 5 | 4/1 | 44.1 (18.9, 31.2-72.5) | 10.3 (7.3, 5.1-13.4) |
Vasculitis | 4 | 3/1 | 69.5 (18.6, 58.7-83.6) | 6.7 (6.1, 3.8-15.9) |
Chondrocalcinosis | 4 | 1/3 | 67.9 (18.8, 46.8-83.6) | 3.7 (2.8, 0.5-10.4) |
GPP | 3 | 2/1 | 55.5 (21.1, 44.3-72.4) | 17.1 (13.4, 8.5-35.5) |
Polychondritis | 3 | 1/2 | 42.2 (27.5, 29.8-66.4) | 9.1 (10.9, 8.3-30.1) |
TRAPS | 3 | 1/2 | 47.8 (29.5, 12.5-51.7) | 31.2 (19.1, 9.3-47.5) |